ClinicalTrials.gg
RecruitingNCT06512935VPOCHUpdated Oct 26, 2026

Ventilator Pressure and Optimization of Compliance and Hemodynamics

An interventional study of Increase in the PEEP followed by decrease in the PEEP and Decrease in the PEEP followed by increase in the PEEP in Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia and Extreme Prematurity, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 7 Days to 30 Days. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 26, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
7 Days to 30 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Bronchopulmonary Dysplasia with a site in United States — 29 open to participants now, 36 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · United States.

Planned enrollment
86th of 117
24 · median 50
Started
2026
with 11 others
No phase
46 of 147
13 open now
Primary completion
2027-05
later than 15 of 35 live
Registered
132nd of 147
by date
Lead sponsor
9 of 147
University of Alabama at Birmingham

Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, this one is the 86th largest by planned enrollment of the 117 interventional ones that give a count, is one of 12 that started in 2026, is one of 46 with no phase, reaches primary completion later than 15 of the 35 other live ones, and was the 132nd registered.

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

Browse Bronchopulmonary Dysplasia studies →

Open to participants now

29 of the 147 studies in Bronchopulmonary Dysplasia with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.

This study: 7 Days to 30 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Bronchopulmonary Dysplasia with a site in United States, or all of them as a file.
02

Study summary

In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.

Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.

Read the detailed description

In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with EIT to optimize ventilator settings in preterm infants.

Neonatal ventilation is a critical intervention to support breathing for newborns with respiratory distress syndrome (RDS), underdeveloped lungs, and evolving bronchopulmonary dysplasia (BPD). Positive airway pressure helps maintain patency of the airways and improves ventilation and oxygenation by maintaining the functional residual capacity (FRC) and keeping the alveoli patent. Peak inspiratory pressure (PIP) and positive end-expiratory pressure (PEEP) are terms commonly used in mechanical ventilation to describe the pressures applied to the respiratory system during the different phases of the breathing cycle. These parameters are essential in managing and optimizing ventilation for infants with respiratory failure.

This study will include preterm infants with recovering RDS born at age \< 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on high-frequency jet ventilation (HFJV). Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and each subsequent PEEP.

Following informed consent, randomization will be performed using sequentially numbered sealed opaque envelopes. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.

This will be a single-center, randomized crossover study. The randomization envelope will be signed before it is opened just before starting the study on each infant to indicate the first intervention for the infant.

Randomization will occur after a baseline assessment of cardiac hemodynamics and respiratory status at the current set PEEP level. Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease versus decrease followed by increase. Randomization will use opaque sealed envelopes of varying block sizes from 2-4 with a 1:1:1:1 allocation ratio.

Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline and there will be a 15-minute washout period after changes before data collection.

All infants enrolled in the study will have routine monitoring, uniform target saturation ranges of 91-95% with alarm limits set at 88-95%, and standard care for the duration of the study. Pulse oximetry recordings will be downloaded using ixTrend (iexcellence, Wildau, Germany) software to a secure computer system for later data analysis.

Infants will continue standard treatment as recommended by the treating physician and will act as their own controls.

Primary secondary outcomes are described below. Electrical impedance tomography data will be collected in the Syntec machine and safely secured in the university computer system. Pulse oximetry recordings will be downloaded using ixTrend software to a secure computer system for later data analysis.

ECHO results will be stored in the unit ECHO machine and results will be reported by certified cardiologists blinded to the data collected to improve the study design's internal and external validity.

03

Conditions studied

  • Bronchopulmonary Dysplasia
  • Pulmonary Hypertension Due to Lung Diseases and Hypoxia
  • Extreme Prematurity
  • Ventilator Lung; Newborn
  • Ventilation Perfusion Mismatch

Keywords

  • Respiratory distress syndrome
  • ventilation mechanics in newborn
  • cardiac hemodynamics newborn
04

Who can participate

Ages eligible
7 Days to 30 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \< 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.

  • Post-natal age > 7 days and less than 1 month (outside golden week protocol)
  • Gestational age ≥ 21 weeks and ≤ 34 week
  • Infants with written obtained from legal guardian

Exclusion criteria

Exclusion Criteria:

  • Blood culture-positive sepsis
  • Congenital anomalies affecting respiration
  • Cyanotic or ductal-dependent congenital heart disease
  • Newborns who are considered too unstable for study enrolment per neonatology attending
  • Newborns on pressors or for maintaining cardiac output
  • Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)
  • Open skin wounds or abrasions on the chest wall.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    cardiac hemodynamics and respiratory status assessment with increasing PEEP

    Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - increase followed by decrease in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT

    Other: Increase in the PEEP followed by decrease in the PEEP

  • Active comparator
    cardiac hemodynamics and respiratory status assessment with decreasing PEEP

    Infants will be randomized to the order of changes in PEEP levels during mechanical ventilation - decrease followed by increase in PEEP. Baseline parameters looking into cardiac hemodynamics as well as compliance and respiratory mechanics will be assessed using EIT

    Other: Decrease in the PEEP followed by increase in the PEEP

Interventions

  • OtherIncrease in the PEEP followed by decrease in the PEEP

    Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

  • OtherDecrease in the PEEP followed by increase in the PEEP

    Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

06

What researchers measure

Primary outcomes

  1. Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT

    Time frame: During a 4 hour cross-over period on either intervention

  2. PEEP of best compliance and best oxygenation as per EIT measurements

    Time frame: During a 4 hour cross-over period on either intervention

Secondary outcomes

  1. Tidal volume variation

    Time frame: During a 4 hour cross-over period on either intervention

  2. Oxygen saturation index

    Time frame: During a 4 hour cross-over period on either intervention

  3. End-expiratory lung impedance (EELI), End-inspiratory lung impedance (EILI)

    Time frame: During a 4 hour cross-over period on either intervention

  4. Transcutaneous carbon dioxide (TcCO2) values in response to varying PEEP levels

    Time frame: During a 4 hour cross-over period on either intervention

  5. Respiratory Severity Score (RSS)

    RSS: mean airway pressure (MAP) x fraction of inspired oxygen (FiO2)

    Time frame: During a 4 hour cross-over period on either intervention

  6. oxygen saturation (SpO2) values

    Time frame: During a 4 hour cross-over period on either intervention

  7. % tidal distribution

    Time frame: During a 4 hour cross-over period on either intervention

07

Study locations

1 of 1 sites recruiting
  • Univerisity of Alabama
    Birmingham, Alabama 35233, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.

Of 71 non-industry interventional studies with no phase under Bronchopulmonary Dysplasia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 7 months is below that.

Counting every sponsor, half of 73 studies reached it within 37 months; a quarter within 19 and three quarters within 63.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 22, 2024
StartActual
Oct 1, 2026was Aug 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Oct 1, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Aug 1, 2026→Oct 1, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06512935
Responsible party
Kulsajan Singh Bhatia (Neonatal Perinatal Fellow, University of Alabama at Birmingham) — Principal investigator
First posted
Jul 22, 2024
Start date
Oct 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Kulsajan S Bhatia, MD
Contact
ksbhatia@uabmc.edu
9172149882
Colm P Travers, MD
Contact
cptravers@uabmc.edu
Kulsajan S Bhatia, MD
principal investigator · University of Alabama at Birmingham
Colm P Travers, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion